A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Clinical trial NCT05698303 · UNKNOWN
Trial details
- NCT number
- NCT05698303
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-08
- Primary completion
- 2024-05-20
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.